Merck & Co. (MRK) analysis

Loading the Vaultflake…

Health is the lab's cash, not a closed protocol. Quality separates Keytruda's margin from the vaccine and from animal health. Growth follows what the payer covers, not irreplaceability. P/E is read against a year of exclusivity, not against that year as normal. Shareholder return is the dividend, checked against that cash. Do not read it as the world's best-selling therapy.

The P/E of a heavy Keytruda year is not the earnings once the patent ends. EV/EBITDA is read without treating the vaccine as an annual prescription. Do not use Bristol's multiple as if Opdivo and Keytruda were the same book. A dash if MRK is missing.

Limits of this report

Not advice on Merck. Vaultflake does not date the patent, does not describe how the vaccine is made, and does not treat Keytruda as irreplaceable. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.

Questions from this report